Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1263066 | 0.88 | LMNA (0.66) | LMNACRHBPCRHR2MAPTPDK1 | |
| SCHEMBL9956838 | 0.83 | TSHR (0.64) | MAPTPDK1MEN1KMT2ATSHR | |
| SCHEMBL31397894 | 0.83 | PDK1 (0.51) | LMNAMAPTPDK1TSHRALDH1A1 | |
| SCHEMBL31397879 | 0.82 | PDK1 (0.50) | LMNAMAPTPDK1MEN1KMT2A | |
| SCHEMBL3440894 | 0.82 | VCAM1 (0.64) | LMNAMAPTPDK1MEN1KMT2A | |
| SCHEMBL28443421 | 0.81 | LMNA (0.61) | LMNACRHBPCRHR2MAPTPDK1 | |
| SCHEMBL28126128 | 0.80 | LMNA (0.60) | LMNACRHBPCRHR2MAPTPDK1 | |
| SCHEMBL31397866 | 0.79 | PDK1 (0.58) | LMNAMAPTPDK1MEN1KMT2A | |
| SCHEMBL263311 | 0.79 | LMNA (0.72) | LMNACRHBPCRHR2MAPTMEN1 | |
| SCHEMBL29793639 | 0.79 | LMNA (0.72) | LMNACRHBPCRHR2MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232272-B2 | Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232272-B2 | Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232272-B2 | Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20100286129-A1 | NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20100286129-A1 | NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20100286129-A1 | NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-2229385-A2 | BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Merck Patent GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009062576-A2 | BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009062576-A2 | BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| EP-2058308-A1 | Benzimidazoledihydrothiadiazinone derivatives used as fructose-1,6-biphosphatase inhibitors and pharmaceutical compositions containing same. | Merck Sante (FR) | 2009-05-13 | — | — | EP | disclosed |
| EP-2058308-A1 | Benzimidazoledihydrothiadiazinone derivatives used as fructose-1,6-biphosphatase inhibitors and pharmaceutical compositions containing same. | Merck Sante (FR) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286129-A1 | NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | FBP1, ALDOA, GCK | LMNA 4631/4885CRHBP 3945/4885CRHR2 4682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.